KENNETH R. SHROYER, MD, PHD
Principal Investigator, SEHLab
Marvin Kuschner Professor and Chairman
Department of Pathology
Stony Brook Medicine
A surgical pathologist and cytopathologist at Stony Brook University Hospital, Dr. Kenneth Shroyer serves as President of the University Pathology Faculty Practice and is the Marvin Kuschner endowed Chair of the Department of Pathology at the Renaissance School of Medicine. He leads the Shroyer Escobar-Hoyos cancer research lab which is funded by a major award from the Pancreatic Cancer Action Network (PanCAN), and is focused on the discovery and validation of cancer biomarkers with the underlying goal of enhancing the diagnostic accuracy for cancer in surgical pathology and cytopathology specimens. In addition, he serves as the Director of the Cancer Program of Stony Brook Universities’ Institute for Clinical Biology and Drug Discovery, Director of the Research Histology Core Laboratory, Scientific co-director of the Stony Brook Biobank, and is a Member of the Internal Executive Committee and Advisory Boards of the Stony Brook Cancer Center.
Dr. Shroyer graduated with a BS in Biology from Colorado College and completed both his PhD in Experimental Pathology and MD at the University of Colorado Health Sciences Center (UCHSC). After completing his residency in Anatomic and Clinical Pathology at the UCHSC, he joined the faculty at UCHSC as an Assistant Professor and was awarded the title of full Professor in 2002. During his time at UCHSC, Dr. Shroyer invented the method of DNP labeling of nucleic acid probes, was a pioneer in the development of methods for in situ hybridization of mRNAS in the early 1980s and was the first to report the molecular analysis of x-chromosome inactivation in archival tissues as a marker of clonality. He also participated in the early validation of tyramide-based signal amplification technology for in situ hybridization and high sensitivity immunohistochemistry. Following his recruitment to Stony Brook University Hospital in 2007, Dr. Shroyer established his laboratory that has transformed from one focused on diagnostic biomarkers to research that is uncovering molecular mechanisms which drive fundamental properties of the most aggressive forms of human cancer, including pancreatic ductal adenocarcinoma (PDAC). Co-directed by Dr. Luisa Escobar-Hoyos, the lab has leveraged mass spectrometry and immunohistochemical approaches to establish that keratin 17 (K17) is more accurate than clinicopathologic assessment to predict patient survival of patients with multiple types of carcinomas. Moving beyond K17 as a prognostic biomarker, they further identified the key molecular mechanisms through which K17 promotes tumor growth as a nuclear shuttle of tumor suppressor proteins and that it reprograms the metabalome to promote glycolysis and pyrimidine biosynthesis. The lab has established functional domains that mediate K17’s ability to serve as a nuclear shuttle, providing a
rational basis for the development of novel pharmacologic approaches in PDAC. Dr. Shroyer's team has strong collaborations throughout Stony Brook University and with basic and translational research scientists at academic institutions throughout the United States that are providing technical and scientific support for their work in cancer metabolomics, bioinformatics, and in the study of post-translational modifications that mediate K17 solubility in cancer and have tremendous experience with orthotopic and transgenic mouse
models of pancreatic cancer, the development of PDAC organoid cultures and patient-derived xenografts, and RNA-Seq data analysis and predictive modeling. The lab also serves as one of Renaissance School of Medicine's most impactful cancer research training sites for undergraduate, graduate, and medical students, as well as for research postdoctoral fellows and clinical research fellows.
Awards: Pancreatic Cancer Action Network Translational Research Award (2018-2019); Cited by Medscape for senior authorship of the most widely read primary research paper in the field of Pathology (December 2017), Best Doctors in America (2009-2014, 2017); Recognition for senior authorship of one of Human Pathology’s top 10 cited articles (2009), Lucien J. Rubinstein Award for the Best Paper on Neuro-oncology (1998); NIH Shanon Award (1992); Robert H. Fennell, Jr., M.D. Award, Department of Pathology, UCHSCC (1992); Edgar and Marion Adler Scholar Award (185-187)
Dr. Shroyer’s ScieENcv